Siemens Fonds Invest GmbH Invests $9 Million in Organon & Co. (NYSE:OGN)

Siemens Fonds Invest GmbH acquired a new stake in Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 603,115 shares of the company’s stock, valued at approximately $8,998,000. Siemens Fonds Invest GmbH owned approximately 0.23% of Organon & Co. at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Pacer Advisors Inc. increased its position in shares of Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Norges Bank bought a new position in shares of Organon & Co. in the fourth quarter valued at $25,258,000. Magnetar Financial LLC grew its stake in shares of Organon & Co. by 560.2% in the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company’s stock valued at $25,878,000 after buying an additional 1,471,731 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Organon & Co. by 23.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company’s stock worth $48,999,000 after buying an additional 629,191 shares during the last quarter. Finally, Invesco Ltd. raised its position in Organon & Co. by 44.6% during the fourth quarter. Invesco Ltd. now owns 2,034,780 shares of the company’s stock worth $30,359,000 after acquiring an additional 627,944 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

NYSE:OGN opened at $8.81 on Friday. The company has a market cap of $2.29 billion, a P/E ratio of 2.65, a P/E/G ratio of 0.90 and a beta of 0.75. The firm’s fifty day moving average price is $12.34 and its two-hundred day moving average price is $14.42. Organon & Co. has a one year low of $8.01 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.89 by $0.13. The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Organon & Co.’s revenue was down 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.22 EPS. Equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 12th. This represents a $0.08 annualized dividend and a yield of 0.91%. Organon & Co.’s dividend payout ratio (DPR) is presently 2.78%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on OGN. Morgan Stanley cut their price target on shares of Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Barclays dropped their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Evercore ISI cut Organon & Co. from an “outperform” rating to an “inline” rating in a report on Friday, May 2nd. Finally, Piper Sandler lowered their price target on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.00.

Insider Activity at Organon & Co.

In other news, CFO Matthew M. Walsh bought 11,400 shares of the company’s stock in a transaction dated Monday, May 5th. The stock was bought at an average price of $8.82 per share, with a total value of $100,548.00. Following the completion of the acquisition, the chief financial officer now owns 144,484 shares of the company’s stock, valued at $1,274,348.88. This represents a 8.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kevin Ali bought 34,000 shares of Organon & Co. stock in a transaction dated Monday, May 5th. The stock was acquired at an average cost of $8.80 per share, with a total value of $299,200.00. Following the transaction, the chief executive officer now owns 282,731 shares of the company’s stock, valued at $2,488,032.80. This trade represents a 13.67% increase in their position. The disclosure for this purchase can be found here. Insiders bought 102,345 shares of company stock worth $902,430 in the last ninety days. 1.96% of the stock is owned by company insiders.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.